International Journal of Technology Assessment in Health Care

Papers
(The TQCC of International Journal of Technology Assessment in Health Care is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
PP114 The Influence Of Implicit Factors On The Health Technology Assessment Deliberative Process: A Survey In Five European Countries62
PP150 The Role Of Expert Consensus In UK Guidance: Patient Selection For Hydrogel Spacer Use During Prostate Cancer Radiotherapy41
PP53 Applying The VALIDATE Approach To Frame The Assessment Of Integrated Care Management In Aortic Valve Stenosis30
PP97 Recommendations For Generating South African Health-Related Quality Of Life Data For Cost-Utility Analyses28
PD35 Mortality And Risk Factors Associated With Dialysis Patients With COVID-19 In A Brazilian Supplementary Health Service28
OP42 Increasing Access To Real-World Data To Move From Health Technology Assessment To Health Technology Management26
PD09 Comparing Long-term Costs Associated With Intraocular Lens Selection And Nd:YAG Laser Capsulotomy In The UK: A Cost-Consequence Analysis26
PP47 Modelling Non-small Cell Lung Cancer Treatment: Predicted and Observed Impact Of Immunotherapy In The Netherlands26
PP23 Lost In Translation? The Differences In The Use Of Real-World Evidence Across Key Markets24
OP92 Impact Of Real-World Evidence On Health Technology Assessment And National Guidance For Interventional Procedures: A UK Perspective21
PP97 How Health Technology Agencies Estimate Target Population Size For Medical Devices: The Example Of Spinal Cord Stimulation19
OP128 Uncertainties In The Cost-Effectiveness Analysis Of Onasemnogene Abeparvovec For Spinal Muscular Atrophy Type 118
PP105 Efficacy, Effectiveness And Safety Of Letermovir For Prophylaxis Of Cytomegalovirus Infection And Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation18
PP38 Designing A Training And Capacity Building Pathway In Patient Involvement16
PP79 Publication Trends Of Network Meta-analyses In Europe And Asia: A Focus On Cardiovascular Disease15
Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury15
OP19 Exploring The Environment/Capacity Of South African Citizen Actors To Contribute To Health Technology Assessment Processes, Policy Development And Institutionalization15
OP60 Methodological Guidance And Doctrine Of The French National Authority For Health For Economic Evaluation15
PD137 Reviewing The Health Technology Assessment And Regulatory Policy Landscape On Acceptability Standards For Real-World Evidence - Initial Findings15
PD149 Comparison Of The Draft European Union Health Technology Assessment Template With Germany’s AMNOG Template14
PD208 Optimal Scheme For Molecular Diagnosis Of BRCA1/2 Gene Mutations In Patients With Breast Cancer In Poland - Cost-Utility Analysis14
PP56 National Immunization Technical Advisory Groups Are Essential For Successful Implementation Of The European Health Technology Assessment Regulation13
OP76 Cost-Effectiveness Of Offering Human Papillomavirus Self-Sampling To Non-Attendees Of Organized Primary Cervical Cancer Screening In Germany13
PD129 Extension Of An Influenza Vaccination Program To Include Those Aged 50 To 64 Years: A Rapid Health Technology Assessment Approach12
OD12 Large Language Models As Powerful Tools In Health Technology Assessment12
PP07 One Bad Apple Can Spoil The Barrel: Are We Effectively Evaluating Software As A Medical Device?12
PD10 Cost Effectiveness Analysis Of Etranacogene Dezaparvovec Versus Factor IX Prophylaxis In Adult Men With Hemophilia B From Brazil10
Mapping frameworks for synthesizing qualitative evidence in health technology assessment9
PP36 Comparing Artificial-Intelligence-Generated And Expert-Driven Chemotherapy Recommendations For Node-Positive Breast Cancer9
PP92 Enhancing Patient Engagement In Health Technology Assessment: Identification Of Barriers, Facilitators, And Proposals For Improvement9
PP86 Cost Effectiveness Of Maternal Respiratory Syncytial Virus (RSV) Prefusion F (RSVpreF) With Complementary Nirsevimab Versus Nirsevimab Alone For Preventing RSV Among Infants In Chile9
OP25 Rapid Molecular Tests For Detecting Multidrug-Resistant Microorganisms: An Overview Of Systematic Reviews Within A Living Evidence Project9
Designing collaborations involving health technology assessment: discussions and recommendations from the 2024 health technology assessment international global policy forum9
OP82 Positron Emission Tomography Combined With Computed Tomography Using 18F-Sodium Fluoride9
Economic evaluation and costs of remote patient monitoring for cardiovascular disease in the United States: a systematic review8
Development and implementation of a value framework for rapid health technology assessment reports: enhancing evidence-informed decision making in resource-constrained settings8
PD33 Exploring The Influence Of Patient Preference Information In Health Technology Assessment: Insights From Mock Deliberations With Agencies8
An operationalization framework for lifecycle health technology assessment: a Health Technology Assessment International Global Policy Forum Task Force report8
Trust, validation, and accountability: implementing uses of generative artificial intelligence into Health Technology Assessment practice8
Reframing early health technology assessment through a lifecycle lens: Commentary on “defining early health technology assessment: building consensus using Delphi technique”8
A consensus-based checklist for the critical appraisal of cost-of-illness (COI) studies8
PP11 Patient Involvement In Drug Evaluations To Inform Funding Decisions: A Singapore Case Study8
From HTA to the bedside: aligning GenAI validation with clinical reality8
OP66 Assessment Of Patient And Public Involvement Reporting In Health Technology Assessment Documents In Brazil (2023 To 2024)8
Health technology assessment in traditional and complementary medicine: a scoping review of international activity and examples of acupuncture8
PP149 A Multidimensional And Multistakeholder Approach: Assessing Ethical, Legal, Organizational, Social or Patient-centered (ELSI+) for Telemedicine In Neurological Diseases7
Next-generation methods in health technology assessment (HTA): need, rigor, and implementability7
OP80 Generating Patient Preference Evidence For Health Technology Assessment: A Sustainable Roadmap7
PP118 Cyclic Mental Health Technology Assessment with Priority Setting And Involving Stakeholders - A Case Report From The Netherlands7
The role of health economics within health technology assessment: past, present, and future – an Austrian perspective7
OP90 Optimizing Health Technology Assessment And Appraisal For Orphan Drug Reimbursement: Experiences And Tools For Improvement7
Considering research waste in economic evaluations of low-dose computed tomography screening for lung cancer7
PP09 Use Of Real-World Evidence For Managing Health Technologies Throughout The Life Cycle Of Transcatheter Aortic Valve Interventions7
PD203 Comparison Of Health Technology Assessment Methodologies Across Australia, Canada, New Zealand And The United Kingdom: Implications For Future Collaboration7
PD71 Survival Outcomes And Adherence To Defined Daily Doses Of Imiglucerase: A 16-Year Brazilian Cohort Study In Gaucher Disease6
OP167 An Analysis Of Medication Exclusion Reports In The Health Technology Assessment Process For The Brazilian Unified Health System6
PD32 Opportunities And Challenges: Health Technology Assessment Body Perspectives On The Integration Of Artificial Intelligence In Evidence Synthesis6
Health technology assessment and healthcare environmental sustainability: Prioritizing effort and maximizing impact6
OP126 Clinical And Economic Evaluation Of The Effectiveness Of Cerebrolysin® In Neurological Patients With Post-Stroke Complications In Kazakhstan6
OP27 Impact Of Generic Entry Of Pharmaceuticals On Drug Prices In Australia6
PP146 Seeing Eye-To-Eye on Real-World Evidence: Are Guidance from Japan and China Consistent with Recommendations from REALISE in Asia?6
OP63 Life Cycle Health Technology Assessment: Brazil’s Experience With CONITEC6
Decision making for early surgical technology adoption into Canada’s healthcare system: a scoping review of the decision-making criteria, challenges, and opportunities6
PP09 Fecal Immunochemical Tests For Patients With Symptoms Suggestive Of Colorectal Cancer: A Systematic Review And Multiple-Threshold Meta-Analysis6
OP46 The Decision Uncertainty Toolkit: Risk Measures And Visual Outputs To Support Health Technology Decision-making During Public Health Crises6
Perception of non-layperson advisory committee members on the application of a discrete choice experiment instrument to patients and advisory committee members: a qualitative study6
A first exploration of the economic consequences of an autonomous surgical robot for lateral skull base surgery: an early health technology assessment6
Use of surrogate endpoints in health technology assessment: a review of selected NICE technology appraisals in oncology5
Acknowledgements5
PP54 Next Generation Sequencing Gene Panel For Medical Lung Cancer Medical Care5
OP17 Updated Cost-Effectiveness Threshold Estimates For 174 Countries Based On Projected Growth In Life Expectancy, Health Expenditure, And Gross Domestic Product5
OD11 Application Of Natural Language Processing To Predict Final Recommendation Of Brazilian Health Technology Assessment Reports5
PD75 Evolution Of Health Technology Submissions In The Unified Health System: Analysis Of National Committee For Health Technology Incorporation (CONITEC) Evaluations (2012 to 2024)5
OP62 Trends In Uncertainties And Outcomes Following An Assessment Of Cancer Topic Suitability For The Cancer Drugs Fund5
OP176 Integrating Real-world Compliance In The Assessment Of Left Atrial Appendage Closure Versus Anticoagulation Therapy In Non-valvular Atrial Fibrillation5
Results of health technology assessments of orphan drugs in Germany—lack of added benefit, evidence gaps, and persisting unmet medical needs5
OP08 A Comprehensive Collaborative Framework To Enhance Orphan Drug Accessibility For Rare Diseases: Insights From Türkiye5
PP13 Access Barriers After The Incorporation Of Technologies Into The Unified Health System In Brazil5
A value framework for lymphoma therapies based on MACBETH method4
PP70 Mapping Of Health Technology Assessment In China: A Comparative Study Between 2016 And 20214
Patient-based evidence: its role in decision making on end-of-life, orphan, and ultra-orphan medicines4
PD33 Development And Validation Of A Machine Learning-Based Prediction Model For COVID-19 Diagnosis Using Patients’ Metabolomic Profile Data4
OP65 An Overview Of Participatory Approaches, Stakeholders, Methods, Topics and Challenges In Medical Device Development: A Scoping Review4
PD22 Exploratory Analysis of a Brazilian Real-World Open Database Applied to Prostate Cancer4
OP44 Does The Health Economic Modelling Structure Matter? An External Validation Of Three Approaches Commonly Used In Obesity Modelling4
A review of HTA guidelines on societal and novel value elements4
Toward including environmental sustainability in Health Technology Assessment4
Unveiling trends: insights into medicines reimbursement recommendations and health technology management in Ireland (2018–2023)4
OP136 A Comparison Of Health Technology Assessment Recommendations In Australia, Canada, And England: Is There Opportunity For Further Alignment?4
OD14 Harmonization Of HTA For Digital Health Technologies: The EU-Funded European Digital Health Technology Assessment Project4
OP105 Gaps, Challenges And Priorities For Neurodegenerative Disease Research And Health Technology Assessment4
PD05 Novel Non-Thermal Ablation Technology For The Treatment Of Atrial Fibrillation4
From task validation to workflow assurance in Health Technology Assessment4
The HTAi early HTA definition: a welcome milestone, and what must follow4
Organizational impact in healthcare in France: a decade of insights but chicken and egg situation4
OP51 Use Of Real-World Data In Cost-effectiveness Analysis Of Sequential Biologic Treatment For Rheumatoid Arthritis4
Health technology assessment 2025 and beyond: lifecycle approaches to promote engagement and efficiency in health technology assessment4
PP111 Reimbursement And Payment Models: A Survey Of Stakeholders’ Current Experiences And Future Outlook Within The Dutch Policy Setting4
Value-based payment for high-cost treatments in Singapore: a qualitative study of stakeholders’ perspectives4
OP163 Applying A Local Economic Evaluation Framework To Make Evaluations More Relevant For Local Decision Makers4
The potential of the hospital-based Health Technology Assessment: Results of a world-wide survey4
Patient perspectives on continuous glucose monitoring system (CGMS) for diabetes in Malaysia: a vital voice in health technology assessment (HTA) informing decision-making3
PP42 Comprehensive Care Program For Polypharmacy Patients: Cafam Experience (Healthcare Provider Institution – Pharmaceutical Manager)3
PP39 Monitoring Clinical Trial Registers In The Context Of A Systematic Review On Vitamin D For COVID-193
OP50 BRISA: Regional Database Of Health Technology Assessment Reports Of The Americas3
Acceptability of self-administered antigen test for COVID-19 in the Philippines3
PD133 Exploring Real-World Data Based Financing Models For Lung Cancer Immunotherapy In The Czech Republic3
PP55 Health Technology Assessment Scoping Definition For Health Regulation3
OP01 Impact Of Cost Heterogeneity On Assessing The Value Of Gene Therapies3
PD177 The Effect Of COVID-19 On Cancer Screening In Brazil, Canada, And The USA: A Cross-National Study3
PD57 Drugs For Chronic Degenerative And Rare Diseases In The Brazilian Public Health System: Profile Of Budget Impact Analyses3
PP51 Critical Analysis Of Budget Impact Analyses For Health Technologies In The Brazilian Supplementary Health System3
OD39 Evaluation Of Sustainability And Environmental Impact Measures In Health Technology Assessment Of Medical Technologies In Europe: Starting An Important Journey3
OP70 Implementation Of An Online Consultation Hub To Facilitate Consumer Engagement In Health Technology Assessment Processes3
PP37 Guidance On Using Hospital-Based Real-World Evidence In Health Technology Assessments For Oncology3
PD199 Global Collaboration Post-Brexit: Do Project Orbis And The Access Consortium Improve Access In The UK Compared With Europe?3
PD124 Genicular Artery Embolization For The Treatment Of Knee Osteoarthritis: A Systematic Review And Meta-analysis3
PD42 Should Antibiotics Be Used To Treat Recurrent Otitis Media In Children? Updating A Recommendation3
A model-based economic analysis of the CFHealthHub intervention to support adherence to inhaled medications for people with cystic fibrosis in the UK3
OP72 Clinical And Economic Impact Of The Availability Of Innovative Therapies For Advanced Lung Cancer In Latin America3
PD68 Access To Medications For Chronic Degenerative And Rare Diseases In The Brazilian Public Health System: 2012 to 20233
PD92 Procedures For Disinvestment Of Health Technologies In Latin America3
PP57 Outcomes Model For Assessing Strategies Improving In Vitro Fertilization Birth Rates3
PD186 Treat-To-Target In Gout: Are Private General Practitioners In Malaysia Riding The Evidence-Based Wave?3
PP34 Impact Of The COVID-19 Pandemic On Depression Incidence And Healthcare Service Use Among Patients With Depression3
PD231 A New Way Of Identifying And Selecting Health Technology Assessment Topics: Using Social Media And Citizen Involvement3
PP09 Automated Study Selection Flowchart: Direct_Flow2
Expanding access to sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the Ministry of Health Malaysia – a multiple HTA approach2
OP79 Incorporating Environmental Impacts Into Health Technology Assessment: An Examination Of Potential Approaches And Challenges2
PP33 Molecular Markers For The Detection Of Clinically Significant Prostate Cancer2
The role of financial distress as a patient-relevant endpoint in early benefit assessments for oncology drugs: a mixed-methods document analysis2
PP120 Fluorescent In Situ Hybridization (FISH) Vs Conventional Cytogenetic (CC) For Detecting High-Risk Genetic Mutations In Multiple Myeloma2
OP13 Improving Case Finding For Celiac Disease In Children And Adults: Evidence Synthesis And Economic Modeling2
PP82 Environmental Sustainability Assessment Across The Medical Device Life Cycle: Taking The Viewpoint Of Low Resource Settings2
PP76 Clinical Guidelines For Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis: Incorporating Rituximab To Enhance Equity In Access And Treatment In Brazil2
Response to heterogeneity of tests and platforms in economic evaluations: synthetic model adoption; derivatives of transferable practice2
PD61 Thromboprophylaxis After Major Orthopedic Surgeries: Health Technology Assessment To Promote Access To Oral Anticoagulants2
PP41 COVID-19 Modeling To Support Decision Making In Brazil: A Scoping Review2
PP87 Glecaprevir/pibrentasvir (Maviret®) Remains A Cost-effective Treatment For Chronic Hepatitis C Virus Infection After Changes To The Treated Population2
PD07 Cost-Effectiveness Of Direct Oral Anticoagulants In Chinese Patients With Non-Valvular Atrial Fibrillation2
Building capacity in horizon scanning, early awareness, and disinvestment: a framework for education and training2
PD50 Does The New Healthcare Reform Improve Job Satisfaction Among Village Clinic Doctors In China? A Meta-Analysis2
OD33 Assessment Tool For MHealth Apps To Manage Depression (EvalDepApps Project)2
PD119 Interventions To Improve Long COVID Symptoms: A Systematic Review Of Randomized Controlled Trials2
PP60 Literature Review For Health Technology Assessment (HTA)-Based Decision Making In Brazil: Artificial Urinary Sphincter For Post-Prostatectomy Severe Urinary Incontinence2
PD21 Evidence Assessment Frameworks And Economic Modeling For Rare Diseases: A Stakeholder Survey Exploring Current Practices In HTA2
OP31 Monitoring Of The Budget Impact Determinants Of Incorporated Technologies For Rare Diseases In The Brazilian Health System2
PD60 The Importance Of Systematic Reviews Addressing Questions Of Prevalence In Health Technology Assessment2
PD96 Are Continuous Noninvasive Blood Pressure Monitoring Devices Accurate Enough To Replace Invasive Monitoring? A Rapid Review2
PP129 Health Technology Assessment Adaptation: Pharyngolaryngeal Biopsies (OLB) For People with Suspected Head and Neck Cancer in the Outpatient Setting2
Closing the gap: do we need a framework for embedding equity in health technology assessment?2
Development and validation of a type 2 diabetes model to estimate the cost-effectiveness of diabetes interventions across the care continuum2
Advancing cooperation in Health Technology Assessment in Europe: insights from the EUnetHTA 21 project amidst the evolving legal landscape of European HTA2
OD30 Clinician-Driven Health Technology Assessment: National Cancer Medicines Review For Off-Label Uses And On-Label Off-Patent Uses In NHSScotland2
OP20 Technical Validation Of An Environmental Model: A Multidisciplinary Checklist To Guide Environmental Criteria In Health Technology Assessment2
PD25 Identification Of Unmet Medical Needs Through A Health Technology Assessment Process To Guide Research And Development: Experience From A University Hospital2
PP45 Budget Impact Analysis Of Including Bictegravir/Emtricitabine/Tenofovir Alafenamide In First-Line Antiretroviral Therapy For HIV/AIDS In Chile’s Explicit Health Guarantees2
PP53 Potential Cost-Effectiveness And Innovation Headroom Of A More Accurate Companion Diagnostic For PD-L1 In Non-Small-Cell Lung Cancer2
PP27 Health Technology Assessment For Obesity Treatment In The Brazilian Public Health System: A Review Of Technology Incorporation Decisions1
PP140 Economic Evaluation Of Several Vaccination Strategies Against Rotavirus In Spain1
PD155 RedETS Horizon Scanning: Impact In The Decision-Making Process1
OP01 Evaluating Health Through The Lens Of Productivity Gains1
PP153 Efficacy And Safety of Onasemnogene Abeparvovec For The Treatment Of Patients With Spinal Muscular Atrophy Type 1: Meta-Analysis1
PP14 Value-Based Pricing For Advanced Therapy Medicinal Products: Emerging Affordability Solutions1
Health technology assessment and innovation: here to help or hinder?1
OD37 How The PICOTS-ComTeC Framework For Digital Health Interventions Can Be Useful For Health Technology Assessment1
PP09 Capturing Broader Effects Of Influenza Vaccination Program In Economic Evaluation: Systematic Literature Review1
OP56 Hospital-Based Health Technology Assessment: Barriers And Facilitators In France, Hungary, Italy, Kazakhstan, Poland, Switzerland, And Ukraine1
OP44 Artificial Intelligence-Based Mobile Health Technology For Improved Access To Dermatological Care: A Kenyan Case Study1
PP03 Investigating Technological Strategies In The Hospital Setting: Insights From The Dutch Context1
Developing and Implementing a Protocol for Evaluating Patient Involvement in Health Technology Assessment: The Experience of the Spanish HTA Network (RedETS)1
OP94 Economic Evidence On Hemodialysis Access Creation Procedures In Patients With End-Stage Kidney Disease: A Systematic Literature Review1
PD179 Navigating Health Crises In Emerging Economies: A Comprehensive Examination Of COVID-19’s Influence On Health Care Access And Resilience1
PP127 Early Health Technology Assessment (HTA) Of Medical Technologies To Inform Subsidy Decision-making In Singapore1
OP47 New Health Technology Assessment Framework For Digital Health Technologies1
PP30 A Costing Template For The Implementation Of A Public And Patient Advisory Board For Health Research In Dementia1
PD225 Implementation Of Hospital-Based Health Technology Assessment For Innovative And Expensive Medical Devices In A French Teaching Hospital1
PP49 Cost Of Cardiac Implantable Electronic Device (CIED) Infections In Australia: A Private And Public Sector Payer Perspective1
National health technology assessment in Turkiye after a decade: are key principles followed?1
PD201 Rare Disease Product Approvals: The Changing Regulatory And Health Technology Assessment Landscape Between 2013 And 20221
OP115 Scoping Meta-Review On Methods Used To Assess Artificial Intelligence-Based Medical Devices For Heart Failure1
PD31 Counting Oncology Patients In The Brazilian Public Health System: A Comprehensive New Methodology1
PD93 Uncertainty Metric To Guide PICOS Assessment And Evidence Synthesis Planning For Joint Clinical Assessment Submission1
PD168 Developing And Implementing A Value Framework For Rapid Health Technology Assessments: Enhancing Evidence-Informed Coverage In Resource-Constrained Settings1
OP74 Assessing Public Confidence Towards COVID-19 Vaccines Through Social Media Insights Leveraged Using Artificial Intelligence Techniques1
The UK early access to medicines scheme: uptake, approvals, and reimbursement1
PP59 Do Patient Contributions Matter? A Thematic Document Analysis Of NICE Ultra-Rare Disease Appraisals1
PP12 Government Agency For Health Technology Assessment In Mendoza, Argentina: Experience And Path1
PP91 Developing A Re-assessment Process For Non-medicine Health Technologies In Wales1
PD01 Advances In The Incorporation Of Medical Devices: A Case Study On Technology Developed By A Brazilian University1
PD39 First Approach For Assessing Statistical Significance In Industry Funded Matching-Adjusted Indirect Comparison Studies: A Scoping Review1
PD39 Health Technology Assessment Processes In Brazil: A Comparative Study Of Public And Private Regulatory Frameworks1
PP108 Multidimensional Analysis Of Peristeen Plus Medical Device1
Approaches to modeling treatment sequencing in practice: a thematic review of prior NICE appraisals1
OP98 Improving Patient Involvement In Health Technology Assessments: Is It Enough To Train Just The Patients?1
PD32 Cost-Utility Of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres For Chemotherapy-Refractory Metastatic Colorectal Cancer In Brazil1
Comparing cost-effectiveness of short-course regimens for drug-resistant tuberculosis treatment in India1
PP24 Creating A Comprehensive Open-Access Health Technology Assessment (HTA) Policy Research Database Through Automated Data Extraction From HTA Reports1
PP109 The Use Of Health Technology Assessment In Decision Making: Evidence From The Balkan Countries1
OD48 Improving Public Understanding Of Health Technology Assessment Decisions1
OP07 Eleven Years Of Conitec: Advances And Challenges Of Patient And Public Involvement In The Brazilian Health Technology Assessment Process1
OP68 Adaptation Of Processes For HTA Of Digital Health Technologies Based On Artificial Intelligence1
OP61 Target Trial Emulation To Determine The Population-Level Cost-Effectiveness Of Multigene Panel Sequencing For Advanced Melanoma1
Incorporating healthcare access and equity in economic evaluations: a scoping review of guidelines1
PD202 Reimbursement Success For Pharmaceutical Products With Noncomparative Data: Are Health Technology Assessment Bodies Well Suited To Embrace Innovations?1
PP71 Hospitalization Costs Associated With Advanced Non-Small Cell Lung Cancer In China: Real World Evidence From Jiangsu1
OP35 Suitability Of Preference Methods Across The Medical Product Lifecycle: A Multicriteria Decision Analysis1
PP21 Examining Clinical Evidence: Incorporation Of Medications For Ultra-Rare Diseases – Descriptive Analysis Of Conitec Reports (2012 to 2022) – Brazil1
OP39 Efficiency Frontier For Relapsing-Remitting Multiple Sclerosis In Brazil: An Approach To System Sustainability1
PP38 Immersion in water during childbirth: A survey to the Spanish National Health System1
PP04 Extrapolating Survival Curves In Oncology: Advancing Economic Modeling To Meet Next-Generation Health Technology Assessment Demands1
PP28 Is My Medicine Suitable For An Outcomes Based Agreement? The Feasibility Conundrum1
PP99 Positron Emission Tomography Combined With Computed Tomography (PET/CT) Using 11-C Methionine (11C-MET)1
PD65 Pilot Project Of Horizon Scanning To Inform The Ukrainian Health System About New HIV/AIDS Health Technologies1
OP67 Considerations Of Treatment Novelty In Health Technology Assessment1
OP100 Patient Perspectives In Value Assessment Frameworks: The Asia Pacific Perspective1
OP06 Percutaneous Transforaminal Endoscopic Discectomy: From Insufficient Evidence To Reimbursement1
OP51 Improving Childhood Cancer Management And Financing In Ghana: Results From Stakeholder Mapping and Analysis1
PD32 Incorporating Environmental Factors Into Health Technology Assessment Submissions: A Scoping Review1
PD59 Inpatient Healthcare Costs And Neonatal Disorders: Insights From The Brazilian Public Health System1
OP05 The Role Of Conditional Reimbursement In The Lifecycle Approach1
PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance1
PP88 Life Cycle Scientific Advice For Health Technology Assessment In Korea1
OD41 Conducting Systematic Reviews On Rare Diseases: Lessons Learned From The European Reference Networks Guidelines Programme1
OP83 Diagnostic Accuracy And Cost Effectiveness Of Automated Ankle Brachial Pressure Index Measurement For Peripheral Arterial Disease In People With Leg Ulceration1
Health technology assessment of diagnostic tests: a state of the art review of methods guidance from international organizations1
PP100 Improving The Assessment Of Effectiveness For Digital Applications Using The B Statistic: Using WtsWrng As A Case Study1
Unloading the excess baggage: key informant interviews with Malaysian stakeholders on healthcare disinvestment initiatives1
PP81 Barriers To Implementation Of Health Technology Assessment1
OP60 Community Funding Prioritization Of Drug Treatments: A Discrete Choice Experiment1
PD226 Integration Of Patient And Clinician Insights Into The European Union Joint Scientific Consultations And Joint Clinical Assessments1
PD88 Methods To Minimize Bias And Mediate Between Evidence And Preferences In Health Decision-Making: The Case Of Therapeutic Ranking1
PP101 A Review Of Health State Utility Values Associated With Herpes Zoster1
OP46 Assessing The Quality Of Pharmacoeconomic Evaluations About Type 2 Diabetes Mellitus Drugs In National Reimbursement Drug List1
OP168 Costs And Effectiveness Of Whole Exome Sequencing (WES) In Patients With Unsolved Rare Disease Through The Diagnostic Pathway1
PP17 Navigating Health Technology Assessment (HTA) Requirements During Development Through Early HTA Scientific Advice: Insights From Companies’ Strategies, Challenges, And Priorities1
PD26 Overscreening For Older Women In Cervical And Breast Cancer Screening In Japan1
Priority setting for health technology adoption at the national level: Lessons learned over 25 years’ experience1
PP13 Cost-Effectiveness Analysis Of Antiandrogen Therapies For Metastatic Castration-Sensitive Prostate Cancer: The Brazilian Healthcare System Perspective1
OP127 The Cost Effectiveness Of Anti-Vascular Endothelial Growth Factor Treatments For Age-Related Macular Degeneration In The Italian Healthcare Setting1
PP87 How Innovative Is The Innovation? Early Experience In Assessing The Innovativeness Of Emerging Medical Technologies In Singapore1
Lifecycle evaluation of medical devices: supporting or jeopardizing patient outcomes? A comparative analysis of evaluation models1
OP93 The Cost Effectiveness Of Antiretroviral Therapy Adherence Interventions In HIV/AIDS Patients: A Systematic Review Of Decision Analytic Models1
PP85 The Cost-Effectiveness Of The Anti-COVID Vaccination Campaign In The Italian Healthcare Setting1
OP102 Towards Universal Health Coverage: Health Technology Assessment Roadmap Development In The Emirate Of Abu Dhabi Involving The Whole Ecosystem1
OP54 The Early Detection And Warning System ‘SINTESIS-New Technologies’: A Horizon Scanning Experience In Spain1
PD24 Innovation In Chronic Obstructive Pulmonary Disease Care: Cost Effectiveness Of A New Self-Management Maintenance Program In The United Kingdom1
PP71 Lessons Learned During Analyses Of Appropriate Hearing Care: Building Bridges Between Patient Organizations, Health Professionals And Insurance Companies1
PP103 Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective1
PD185 Is The Incorporation Of Medications For Ultrarare Diseases In Brazil Predominantly Driven By Costs? A Shift In Paradigm1
0.068281888961792